Biotechnology - Biotechnology, Respiratory and Pulmonary

Filter

Popular Filters

1 to 25 of 76 results

AstraZeneca inks deal with Orca for autoimmune disease drugs

AstraZeneca inks deal with Orca for autoimmune disease drugs

25-02-2015

Anglo-Swedish pharma major AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company,…

AstraZenecaBiotechnologyImmunologicalsInflammatory diseasesLicensingOrca PharmaceuticalsRespiratory and PulmonaryUK

Actelion posts strong 2014 earnings growth, but sales shy of expectations

Actelion posts strong 2014 earnings growth, but sales shy of expectations

16-02-2015

Switzerland-based Actelion this morning reported financial results for full-year 2014, showing that sales…

ActelionBiotechnologyFinancialRespiratory and Pulmonary

AnaMar to focus on severe inflammation and fibrosis

28-01-2015

Swedish privately-held biopharma company AnaMar says it will focus pipeline development on severe inflammation…

AnaMarBiotechnologyInflammatory diseasesLicensingResearchRespiratory and Pulmonary

Vectura links with Janssen on asthma/COPD drug development

Vectura links with Janssen on asthma/COPD drug development

06-01-2015

UK inhaled therapies developer Vectura Group has entered into a global development and licence agreement…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingResearchRespiratory and PulmonaryVectura

Boehringer Ingelheim and BioMed X to collaborate on COPD research

Boehringer Ingelheim and BioMed X to collaborate on COPD research

05-01-2015

German family-owned drug major Boehringer Ingelheim is to collaborate with the BioMed X Innovation Center.

BiotechnologyBoehringer IngelheimGermanyResearchRespiratory and Pulmonary

GlaxoSmithKline files for US and EU approval of mepolizumab

GlaxoSmithKline files for US and EU approval of mepolizumab

05-11-2014

UK pharma major GlaxoSmithKline says it has filed regulatory submissions in the USA and Europe for mepolizumab…

BarclaysBiotechnologyBosatriaEuropeGlaxoSmithKlineImmunosuppressantsmepolizumabRegulationRespiratory and PulmonaryUnited StatesUSA

Bristol-Myers enters option agreement to acquire Danish firm

Bristol-Myers enters option agreement to acquire Danish firm

03-11-2014

US pharma major Bristol-Myers Squibb has entered into an exclusive option agreement to buy Denmark-based…

BiotechnologyBristol-Myers SquibbGalecto BiotechMergers & AcquisitionsRespiratory and PulmonaryTD139

BioOutsource preparing for biosimilars boom

03-11-2014

Scotland, UK-based vaccine and microbiological testing company BioOutsource today announced a major initiative…

Anti-Arthritics/RheumaticsBioOutsourceBiosimilarsBiotechnologyResearchRespiratory and Pulmonary

GSK expands collaboration with Five Prime Therapeutics

GSK expands collaboration with Five Prime Therapeutics

27-10-2014

US biotech firm Five Prime Therapeutics is expanding its respiratory disease research collaboration with…

BiotechnologyFive Prime TherapeuticsGlaxoSmithKlineLicensingResearchRespiratory and Pulmonary

Actelion beats expectations as third-qtr net profit rockets 39%

Actelion beats expectations as third-qtr net profit rockets 39%

21-10-2014

Switzerland’s Actelion, Europe’s largest biotech company, this morning announced third-quarter 2014…

ActelionBiotechnologyFinancialOpsumitRespiratory and PulmonarySwitzerlandTracleer

ERS 2014: AMBITION study of ambrisentan/tadalafil combo meets primary endpoint in PAH

ERS 2014: AMBITION study of ambrisentan/tadalafil combo meets primary endpoint in PAH

08-09-2014

US biotech major Gilead Sciences today released results from the AMBITION study (a randomized, double-blind,…

Ambrisentan TabletsBiotechnologyGilead SciencesGlaxoSmithKlineInternational CongressOrganic chemistryResearchRespiratory and PulmonaryTadalafilUSA

ERS 2014: Encouraging new data with AstraZeneca’s benralizumab

ERS 2014: Encouraging new data with AstraZeneca’s benralizumab

08-09-2014

Anglo-Swedish drug major AstraZeneca today announced that The Lancet Respiratory Medicine has published…

AstraZenecabenralizumabBiotechnologyCOPDGermanyHealth Medical PharmaPulmonologyResearchRespiratory and PulmonaryRespiratory therapyUK

Analysis of Roche’s InterMune acquisition

Analysis of Roche’s InterMune acquisition

28-08-2014

The acquisition of InterMune gives Swiss drug major Roche a substantial opportunity, owing to the Breakthrough…

BiotechnologyIdiopathic pulmonary fibrosisInterMuneMergers & AcquisitionspirfenidonePulmozymeRespiratory and PulmonaryRocheSwitzerlandXolair

Vertex received European approval for CF drug Kalydeco

Vertex received European approval for CF drug Kalydeco

01-08-2014

US biotech firm Vertex Pharmaceuticals has announced that the European Commission has approved Kalydeco…

BiotechnologyCommittee for Medicinal Products for Human UseCystic fibrosisKalydecoPharmaceuticalRegulationRespiratory and PulmonaryUSAVertex Pharmaceuticals

VIDEO: Verona Pharma's CEO speaks about its lead product and business opportunities

VIDEO: Verona Pharma's CEO speaks about its lead product and business opportunities

28-07-2014

Jan-Anders Karlsson, chief executive and director of UK-based biotechnology company Verona Pharma, has…

BiotechnologyBusiness FinanceBusiness FinanceHealth Medical PharmaHealth Medical PharmaInterviewsRespiratory and PulmonaryRPL554Technology InternetUKVerona Pharma

Strong first-half 2014 sales and earnings growth for Actelion

Strong first-half 2014 sales and earnings growth for Actelion

22-07-2014

Switzerland’s Actelion, Europe’s largest biotech company, this morning posted a strong set of financial…

ActelionBiotechnologyFinancialOrphan drugsRespiratory and Pulmonary

US breakthrough status for InterMune’s pirfenidone

US breakthrough status for InterMune’s pirfenidone

21-07-2014

US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation…

BiotechnologyEsbrietFood and Drug AdministrationInterMunepirfenidoneRare diseasesRegulationRespiratory and PulmonaryUSA

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

14-07-2014

Anglo-Swedish drug major AstraZeneca’s recent $230 million deal with British respiratory drug development…

AsthmaAstraZenecaBiotechnologyInterferonLicensingRespiratory and PulmonaryRespiratory therapySNG001SynairgenUK

Actelion shares leap on positive Ph III data with selexipag

Actelion shares leap on positive Ph III data with selexipag

16-06-2014

Shares of Switzerland-based Actelion, Europe’s largest biotech firm, gained 15.1% to 104.70 Swiss francs…

ActelionBiotechnologyResearchRespiratory and Pulmonaryselexipag

AADi in-licenses Celgene’s ABI-009

20-05-2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene. Financial…

AADiABI-009BiotechnologyCardio-vascularCelgeneOncologyRespiratory and Pulmonary

Boehringer’s nintedanib slows IPF disease progression in Ph III trial

19-05-2014

Results from the Phase III INPULSIS trials, published on-line yesterday in the New England Journal of…

BiotechnologyBoehringer IngelheimnintedanibResearchRespiratory and Pulmonary

Aslan Pharma signs agreement with CSL to develop novel therapy for asthma

19-05-2014

Singapore-based Aslan Pharmaceuticals has signed a global license agreement to develop an anti-interleukin…

ASLAN PharmaceuticalsBiotechnologyCSL LimitedCSL334LicensingRespiratory and Pulmonary

Ario Pharma strengthens scientific advisory board with two key appointments

Ario Pharma strengthens scientific advisory board with two key appointments

12-05-2014

UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes…

BiotechnologyBoardroomPharmaceuticalRespiratory and PulmonaryUK

Cytos Biotech to wind down key operational activities

05-05-2014

Switzerland-based Cytos Biotechnology has entered into agreements with major creditors resulting in a…

BiotechnologyCYT003Cytos BiotechnologyFinancialLicensingRespiratory and Pulmonary

1 to 25 of 76 results

Back to top